Investment Thesis
Sight Sciences is a pre-profitability medical device company facing a critical juncture with exceptional 86% gross margins undermined by declining revenue (-3.1% YoY), massive operating losses (-63% margin), and negative operating cash flow (-$7.0M). Without rapid revenue growth and operational efficiency improvements, the company's cash runway will be insufficient to reach profitability.
Strengths
- Exceptional gross margin of 86.2% demonstrates strong product-market fit and pricing power in surgical instruments market
- Strong cash position of $85.0M with excellent liquidity ratios (5.86x current, 5.48x quick) provides operational cushion
- Moderate leverage with 0.79x debt/equity ratio offers financial flexibility for strategic reallocation
Risks
- Revenue declining 3.1% YoY with stagnant $19.7M base—no growth trajectory and shrinking top line
- Operating margin of -63% and operating cash burn of -$7.0M indicate fundamentally unscalable business model despite product quality
- Negative interest coverage ratio of -9.8x and sustained cash burn create existential runway risk if revenue inflection does not materialize soon
Key Metrics to Watch
- Quarterly revenue growth rate—must reverse negative YoY trend to validate market demand
- Operating expense ratio trajectory—path to operating profitability is only viable with structural cost reductions given stalled revenue
- Monthly operating cash burn and quarters of cash runway remaining—critical for survival timeline assessment
Financial Metrics
Revenue
19.7M
Net Income
-13.0M
EPS (Diluted)
$-0.24
Free Cash Flow
-7.1M
Total Assets
109.7M
Cash
85.0M
Profitability Ratios
Gross Margin
86.2%
Operating Margin
-63.0%
Net Margin
-65.9%
ROE
-24.1%
ROA
-11.8%
FCF Margin
-36.0%
Balance Sheet & Liquidity
Current Ratio
5.86x
Quick Ratio
5.48x
Debt/Equity
0.79x
Debt/Assets
50.9%
Interest Coverage
-9.79x
Long-term Debt
42.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T12:20:20.782065 |
Data as of: 2026-03-31 |
Powered by Claude AI